753 related articles for article (PubMed ID: 23590560)
1. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
4. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
5. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.
Lemos LL; de Oliveira Costa J; Almeida AM; Junior HO; Barbosa MM; Kakehasi AM; Acurcio FA
Rheumatol Int; 2014 Oct; 34(10):1345-60. PubMed ID: 24728068
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
[TBL] [Abstract][Full Text] [Related]
7. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
8. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
[TBL] [Abstract][Full Text] [Related]
9. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
10. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
11. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):133-7. PubMed ID: 21701796
[TBL] [Abstract][Full Text] [Related]
13. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
[TBL] [Abstract][Full Text] [Related]
15. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
16. Psoriatic arthritis: treatment strategies using biologic agents.
D'Angelo S; Palazzi C; Olivieri I
Reumatismo; 2012 Jun; 64(2):113-21. PubMed ID: 22690388
[TBL] [Abstract][Full Text] [Related]
17. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
18. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
Cawson MR; Mitchell SA; Knight C; Wildey H; Spurden D; Bird A; Orme ME
BMC Musculoskelet Disord; 2014 Jan; 15():26. PubMed ID: 24444034
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of biological treatments in refractory rheumatoid arthritis.
Gallego-Galisteo M; Villa-Rubio A; Alegre-del Rey E; Márquez-Fernández E; Ramos-Báez JJ
J Clin Pharm Ther; 2012 Jun; 37(3):301-7. PubMed ID: 21831256
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):193-4. PubMed ID: 22005889
[No Abstract] [Full Text] [Related]
[Next] [New Search]